Autofluorescence and ultrasound represent the imaging technologies applied to diagnostic bronchoscopy that have found the largest resonance in recent decades [1,2]. Autofluorescence bronchoscopy (AFB) has gained an established role in the diagnosis of preneoplastic lesions or intraepithelial lung cancer [1][2][3][4]. Endobronchial ultrasound (EBUS) has been used for multiple purposes, such as [1,[5][6][7]: 1) facilitating identification and aspiration from hilar and mediastinal lesions in close contact with the airway's wall; 2) guiding transbronchial biopsies in patients with peripheral lesions; 3) differentiating airway invasion versus compression, as well as helping to determine the depth of invasion in patients with central airway tumours.
Autofluorescence bronchoscopyThe outcome of patients diagnosed with lung cancer is fairly poor, and the chances of survival are largely dependent on the stage of the disease allowing for curative surgery [8]. AFB is a screening measure that has been developed in an attempt to identify high-risk patients harbouring pre-neoplastic and early neoplastic lesions in their central airways [9]. The use of AFB is based on the observation that moderate to severe dysplasia and carcinoma in situ (CIS) show less fluorescence than normal tissue when excited by light with wave length ranging from 380-460 nm.In the multicentric study leading to FDA approval, Lam et al. investigated the additional role of AFB, when added to white light bronchoscopy (WLB), in the identification of moderate/severe dysplasia and CIS in 173 patients with known or suspected lung cancer (Level of evidence: III) [3]. The investigators found that AFB + WLB had a relative sensitivity of 6.3 compared to WLB alone. The specificity of AFB was 66%.Many subsequent literature studies (Level of evidence: III) including varying categories of patients with known/suspected lung cancer, or at high-risk of developing lung cancer, confirmed the superiority of AFB + WLB versus WLB in the detection of dysplasia and CIS, even though the relative sensitivity of AFL + WLB was usually found to be lower than that reported in the 1998 study by Lam et coll [10][11][12][13].More recently, the first prospective, randomised, multicentric study compared WLB + AFB versus WLB in 1173 smokers with additional risk factors for lung cancer (Level of evidence: Ib) [4]. The results of this study confirmed the superiority of AFB over WLB in the detection of preneoplastic and early neoplastic lesions, but did not support the high expectations raised by many previous studies. First, the prevalence of isolated pre-invasive lesions was much lower (3.9%) than in most former studies, probably due to the fact that the latter ones often included tumour associated lesions. Second, the relative sensitivity of WLB + AFB versus WLB alone found in this study (1.42) was much lower than in many previous studies, and the superiority of AFB over WLB was statistically significant only for moderate/severe dysplasia and not for CIS. The specificity was 58% for WLB + AF...